Comparison
DSIP vs. Hexarelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Growth
CAS no.
62568-57-4
140703-51-1
Molecular weight
848.81 g/mol
887.05 g/mol
Half-life
0.1 h
0.9 h
Sequence
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluHis-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2Mechanism of action
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Hexarelin
Hexarelin is a synthetic analog of the GHRP-6 family binding both the GH secretagogue receptor (GHSR-1a) and CD36. GHSR activation in the pituitary releases pulsatile growth hormone. Via CD36 in endothelium and myocardium, cardioprotective effects have been described in animal studies.
Evidence base
Highest evidence
Human trial
Human trial
Studies
4
4
of which in humans
1
3
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
1
1